Shahrin Ahmed: The treatment of multiple myeloma is being improved
Shahrin Ahmed, Medical Specialist oncology at Canadian Cancer Society and Associate Professor at Staffordshire University, shared a post on X:
“The treatment of multiple myeloma is being improved –
The number of hematological malignancies globally with multiple myeloma (MM) is the second most frequent. While the disease is known for its aggressiveness and death, recent advances in treatment have significantly improved patient outcomes.
Proteasome inhibitors like bortezomib, carfilzomib, ixazomib, and monoclonal antibodies have all been developed to provide innovative therapies with fewer side effects over the past decade. Immunomodulators like thalidomide, lenalidomide, doxorubidomide, and corticosteroids like dexamethasone are some of the options available, including daratumumab, isatuximab, and elotuzumab.
These agents have been shown to improve efficacy when combined in regimens that target multiple pathways simultaneously.
By targeting myeloma cells more precisely, these therapies can improve patient quality of life, prolong remission, and delay disease progression. Through drug development and combination treatments, the potential for a cure is highlighted due to the evolution of MM therapies.
In 2022, according to global statistics from IARC and WHO, In 2023, there was an increase in diagnoses by 187,952 and deaths by 121,388 due to MM.
In 2023, statistical data from the United States indicates that men are more likely to experience migraines, both in terms of incidence and mortality. The disease caused approximately 2,000 more deaths than women, and men made up more than 50% of the 35,730 new cases reported that year.
Developing therapeutic strategies for multiple myeloma, emphasizing the shift from conventional treatments to novel targeted therapies. Combining advances in drug development, genetic insights, and supportive care.
These innovations have impacted patient management and outcomes, with the objective of enhancing treatment protocols and paving the way for a potential cure highlighted in the study.
Patient survival and quality of life have been significantly improved due to remarkable advancements in the treatment landscape for multiple myeloma (MM).
Disease management has undergone a transformation with the use of targeted therapies and combination regimens, such as lenalidomide, carfilzomib, and bendamustine, that provide greater and sustained results while minimizing side effects.
Maintenance strategies post-transplantation have become more reliant on these therapies that have prolonged progression-free survival.”
More posts featuring Shahrin Ahmed.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023